Mathias Schmid

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Max S. Topp, Peter Kufer, Nicola Gökbuget et al. · Journal of Clinical Oncology · 2011 · 902 citations · Full text

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

Michael Lübbert, Björn Rüter, Rainer Claus et al. · Haematologica · 2011 · 230 citations · Full text

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia

Andrea Kuendgen, Mathias Schmid, Richard F. Schlenk et al. · Cancer · 2005 · 223 citations · Full text

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

Norbert Gattermann, Carlo Finelli, Matteo Giovanni Della Porta et al. · Leukemia Research · 2010 · 177 citations

Hematological Malignancy, Bone Marrow Failure, Iron Metabolism +7

Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes

N. Gattermann, Carlo Finelli, Matteo Giovanni Della Porta et al. · Haematologica · 2012 · 170 citations · Full text